Joe Newell - 22 Sep 2021 Form 4 Insider Report for Atara Biotherapeutics, Inc. (ATRA)

Role
Chief Operations Officer
Signature
/s/ David Tucker, Attorney-in-Fact for Joe Newell
Issuer symbol
ATRA
Transactions as of
22 Sep 2021
Transactions value $
-$229,425
Form type
4
Filing time
24 Sep 2021, 17:35:59 UTC
Previous filing
17 Sep 2021
Next filing
17 Nov 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATRA Common Stock Options Exercise $128K +10.5K +8.76% $12.15* 130K 22 Sep 2021 Direct F1
transaction ATRA Common Stock Sale -$179K -10.5K -8.05% $17.00* 120K 22 Sep 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATRA Employee Stock Option (Right to Buy) Options Exercise -$142K -8.38K -19.36% $17.00* 34.9K 22 Sep 2021 Common Stock 8.38K $12.15 Direct F1, F2
transaction ATRA Employee Stock Option (Right to Buy) Options Exercise -$36.1K -2.13K -16.67% $17.00* 10.6K 22 Sep 2021 Common Stock 2.13K $12.15 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020.
F2 1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2020, subject to the reporting person's continuous service.